Retatrutide Tracker App
Phase 3 Data Is In. Track What Matters.
Shotlee is the free way to track your protocol while retatrutide advances through Phase 3. In the first Phase 3 readout (TRIUMPH-4, December 11, 2025), the highest dose averaged 28.7% weight loss at 68 weeks with major improvements in knee osteoarthritis pain and function.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly that simultaneously activates GIP, GLP-1, and glucagon receptors. Unlike approved dual agonists such as tirzepatide (Mounjaro/Zepbound), the added glucagon component is designed to increase energy expenditure in addition to reducing appetite — potentially driving deeper weight loss in high-need populations.
Phase 2 data published in The New England Journal of Medicine (2023) reported up to 24.2% mean weight loss at 48 weeks. Phase 3 TRIUMPH-4 — the first readout from eight planned Phase 3 studies — exceeded that benchmark at 68 weeks and demonstrated simultaneous improvements in knee osteoarthritis pain and physical function, suggesting broad cardiometabolic utility.
Key Biohacking Mechanics
Phase 3 Snapshot: TRIUMPH-4 (68 Weeks)
TRIUMPH-4 Full Results
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Mean weight change (68 weeks) | -26.4% | -28.7% | -2.1%Best |
| Mean pounds lost | -64.2 lbs | -71.2 lbs | -4.6 lbs |
| WOMAC pain score change | -4.5 points | -4.4 points | -2.4 points |
| Achieved ≥25% weight loss | 47.7% | 58.6% | 1.3% |
| Achieved ≥30% weight loss | 30.5% | 39.4% | 0.8% |
| Achieved ≥35% weight loss | 18.2% | 23.7% | 0.0% |
| Nausea rates | 38.1% | 43.2% | 10.7% |
| Discontinued due to adverse events | 12.2% | 18.2% | 4.0% |
TRIUMPH Development Timeline
What to Track in Shotlee Right Now
Build clean baseline data today so you have a precise comparison point when retatrutide reaches approval.
What This Means for Your Tracking Right Now
Retatrutide now has early Phase 3 validation in a high-need obesity population, but it remains investigational. You cannot prescribe it yet outside trials. That makes your current protocol quality even more important.
Use Shotlee to build clean baseline data now: body weight trend, dose consistency, appetite changes, GI symptoms, blood pressure, body composition, and lab markers. If you later switch medications, that historical data lets you compare outcomes with precision instead of guesswork.
Shotlee supports current GLP-1 and dual agonist protocols today, so you can stay systematic while the remaining TRIUMPH Phase 3 results arrive through 2026.
Retatrutide vs Tirzepatide: Key Differences
- ⚡Targets GIP + GLP-1 + glucagon receptors
- ⚡28.7% mean weight loss at 68 weeks (Phase 3)
- ⚡Investigational — not yet FDA approved
- ⚡Unique glucagon component boosts energy expenditure
- ⚡Phase 3 TRIUMPH-4: co-primary OA endpoints met
- ✓Targets GIP + GLP-1 receptors only
- ✓22.5% mean weight loss at 72 weeks (SURMOUNT-1)
- ✓FDA approved for obesity (Zepbound) and T2D (Mounjaro)
- ✓Proven real-world safety and efficacy data
- ✓Available now — track your protocol in Shotlee
Protocol FAQs
Lilly reported the first Phase 3 topline data from TRIUMPH-4 on December 11, 2025. At 68 weeks, participants on retatrutide 12 mg averaged 28.7% weight loss (71.2 lbs), while placebo averaged 2.1%. Shotlee helps you track your current treatment and prepare for this launch.
As of March 2026, retatrutide is still investigational and not FDA approved. TRIUMPH Phase 3 readouts are still ongoing. Use the Shotlee app to track this timeline and your current protocol.
Mounjaro and Zepbound use dual agonism (GIP + GLP-1). Retatrutide uses triple agonism (GIP + GLP-1 + glucagon), which adds increased energy expenditure on top of appetite control. Phase 3 data suggests deeper weight loss in high-need cohorts. Track and compare outcomes in Shotlee.
Track your current medication doses, side effects, body weight, measurements, and labs in Shotlee now, so you have solid baseline trend data if retatrutide becomes available. The Shotlee app keeps this history clean and easy to review with your prescriber.
Eli Lilly expects seven additional TRIUMPH Phase 3 readouts in 2026. Regulatory submission would follow if results confirm efficacy and safety. A realistic launch timeline — assuming a successful FDA filing — would be 2027 at the earliest. Follow Shotlee's tracker pages for updates.
Start Tracking Your Protocol today.
Build clean baseline data in Shotlee now. When retatrutide launches, you will have the history needed to compare outcomes with precision.
📚References & sources
Latest on Retatrutide
Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
7 min read
Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
7 min read
Retatrutide's Rapid Weight Loss: Balancing Benefits and Risks
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
8 min read